Erba, H. P., Kantarjian, H. M., Claxton, D., Arellano, M., Lyons, R., Kovacsovics, T., … Faderl, S. (2008). Phase II study of single agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy. In Journal of Clinical Oncology (Vol. 26, pp. 7025–7025). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2008.26.15_suppl.7025

Erba, H. P., H. M. Kantarjian, D. Claxton, M. Arellano, R. Lyons, T. Kovacsovics, J. Gabrilove, S. Eckert, R. Abichandani, and S. Faderl. “Phase II study of single agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy.” In Journal of Clinical Oncology, 26:7025–7025. American Society of Clinical Oncology (ASCO), 2008. https://doi.org/10.1200/jco.2008.26.15_suppl.7025.

Erba HP, Kantarjian HM, Claxton D, Arellano M, Lyons R, Kovacsovics T, et al. Phase II study of single agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2008. p. 7025–7025.

Erba, H. P., et al. “Phase II study of single agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy.” Journal of Clinical Oncology, vol. 26, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2008, pp. 7025–7025. Crossref, doi:10.1200/jco.2008.26.15_suppl.7025.

Erba HP, Kantarjian HM, Claxton D, Arellano M, Lyons R, Kovacsovics T, Gabrilove J, Eckert S, Abichandani R, Faderl S. Phase II study of single agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2008. p. 7025–7025.